Cole-Parmer Instrument Co.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cole-Parmer Instrument Co.
Following their asset swap last year, GSK handed over to Novartis complete ownership of the CD20 antagonist ofatumumab; Greatbatch acquired privately held Lake Region Medical Holdings for $1.74 billion in cash and stock. Biopharma financing decreased while device fundraising jumped.
Device financing decreased to $734 million in Q3, less than half the Q2 total, and the $4.9 billion in M&As was a sharp decline versus Q2. Diagnostics fundraising, at $399 million, showed a 31% drop from Q2, and Merck KGAA’s $16.7 billion buy of Sigma-Aldrich made up 96% of the Q3 M&A activity.
For $635 million, Baxter acquired two marketed infectious vaccines from Pfizer; after five offers, Shire accepted AbbVie’s bid for $53.3 billion. Biopharma firms raised a total of $5.7 billion in June and July, while device companies raked in $924 million.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.